

1 The BDNF/TrkB pathway in Somatostatin-expressing neurons suppresses 2 cocaine-seeking behaviour

3 Giuliano Didio¹, Teemu Aitta-aho², Juzoh Umemori³, Eero Castrén¹

4

5 1 Neuroscience Center, University of Helsinki;

6 2 Department of pharmacology, University of Helsinki;

7 3 Gene and cell technology, A.I: Virtanen Institute, University of Eastern Finland

8 *Corresponding authors:

9 Eero Castren, MD, PhD, Neuroscience Center - HILIFE, Haartmaninkatu 8, P.O. Box 63; Zip Code: 00014; Helsinki, Finland.

10 eero.castren@helsinki.fi

11 Juzoh Umemori, PhD Senior researcher, Gene and cell technology A.I. Virtanen Institute, University of Eastern Finland 70211 Kuopio,
12 Finland, juzoh.umemori@uef.fi

13

14 Abstract

15 Cocaine addiction is a highly debilitating condition consisting of compulsive self-administration and
16 seek for the substance of abuse, and its most challenging feature is the high rate of relapse.
17 Addiction and relapse share similarities with neural plasticity which acts through the Brain-Derived
18 Neurotrophic Factor and its receptor TrkB. Somatostatin (SST) expressing interneurons are involved
19 in neuronal plasticity and are important in modulating cocaine-seeking behaviour in mice. We
20 tested the role of TrkB in Somatostatin (SST)-expressing neurons in the extinction of cocaine-
21 seeking behaviour, using mice in which TrkB has been knocked out specifically in SST neurons. We
22 have observed that in these mice, once a cocaine-conditioned place preference is acquired, its
23 extinction through seven days of extinction training is impaired, showing how this process relies on
24 neural plasticity in SST neurons. When we promoted plasticity during extinction training using a
25 light-activable TrkB in SST neurons in the prefrontal cortex of cocaine-conditioned mice, relapse of
26 cocaine-seeking was prevented. Our data identify the critical role of TrkB-mediated plasticity within
27 SST neurons in the extinction of and relapse to cocaine addiction.

28

29 **Keywords:** Neural Plasticity, Mouse behaviour, Addiction, Somatostatin, Cocaine

30

31

32

33

34 1. Introduction

35 Addiction is a debilitating condition characterized by compulsive self-administration and a
36 relentless pursuit of the substance of abuse and its most challenging aspect is the high rate of
37 relapse, even after prolonged periods of abstinence (Brandon, Vidrine, and Litvin 2007).
38 In 2010 alone, European Union countries collectively spent 7.6 billion euros on hospital treatments
39 for addiction, which highlights the significant societal and economic impact of this condition
40 (Lievens, Laenen, and Christiaens 2014). The neurobiological underpinnings of addiction involve
41 several key brain areas, including the ventral tegmental area (VTA) during the binge/intoxication
42 stage, the amygdala for the withdrawal/negative affect stage, and the orbitofrontal cortex, medial
43 prefrontal cortex (mPFC), striatum, nucleus accumbens (NuAcc), hippocampus, and amygdala
44 during the preoccupation/anticipation stage (Koob and Volkow 2010).

45
46 Similarities between the development of addiction and neural plasticity suggest a complex
47 interplay between the brain's adaptive mechanisms and the compulsive behaviors associated with
48 addiction (Jones and Bonci 2005). The Brain-derived Neurotrophic Factor (BDNF) and its receptor
49 neuronal receptor tyrosine kinase-2 (NTRK2, TrkB) are considered the main molecular switches of
50 neural plasticity (Begni, Riva, and Cattaneo 2017), in fact deletion of BDNF in mice impairs LTP in
51 hippocampal slices(Korte et al. 1995), and this effect can be rescued with long BDNF administration
52 (Patterson et al. 1996). BDNF acts by binding to its receptor TrkB, activating it's tyrosine kinase
53 activity (Klein et al. 1989, 1991; Minichiello 2009) which in turn activates a cascade of secondary
54 messengers, eventually leading to the phosphorylation of the transcription factor CREB, and
55 promotion of plasticity-related genes (Finkbeiner et al. 1997; Minichiello et al. 2002). The
56 BDNF/TrkB pathway is involved not only in LTP but also in neurogenesis, synaptic transmission and
57 learning and memory (Bath, Akins, and Lee 2012; Bramham and Messaoudi 2005; Kang and
58 Schuman 1995; Lee, Duan, and Mattson 2002; Li et al. 2008; Poo 2001).I

59
60 Increasing evidence is showing the involvement of BDNF/TrkB in the development and treatment
61 of drug addiction (Jones and Bonci 2005; Nestler 2005).For example, it has been shown that the
62 BDNF/TrkB pathway is necessary for the behavioral effects usually observed after cocaine
63 administration (Hall et al. 2003). Mice with a heterozygous BDNF knockout displayed a lower
64 cocaine-induced hyperlocomotion and showed a lower rate of cocaine-conditioning place
65 preference (Hall et al. 2003). Moreover, in rats trained to self-administer cocaine and then exposed
66 to long drug withdrawal, cocaine craving increased over time and BDNF (but not NGF) increased in
67 VTA, NuAcc and amygdala as the time of drug withdrawal increased (Grimm et al. 2003). In rats
68 after 4h of cocaine self-administration, there is an increase in the BDNF levels in NuAcc, and
69 infusion of BDNF or BDNF-antibody in the NuAcc, increased or decreased respectively the cocaine
70 self-administration and relapse (Graham et al. 2007). TrkB seems to be necessary for the
71 development of cocaine-conditioned place preference (Crooks et al. 2010) and for the beneficial
72 effects of environmental enrichment in preventing relapse of a pre-learned cocaine self-
73 administration (Hastings et al. 2020). TrkB is widely expressed in the brain and in most of neurons,
74 therefore the evidence mentioned so far does not clarify the role of single types of neurons in the
75 regulation of addiction.

77 In the last years inhibitory neurons have gained attention as possible key players in addiction and
78 other mental illnesses (Ostroumov and Dani 2018). SST-neurons are the second largest group of
79 inhibitory neurons, representing 30% of the interneuronal population, present in all cortical layers
80 (except for layer 1), they are generally classified as Martinotti and non-Martinotti cells (Tremblay,
81 Lee, and Rudy 2016), with the majority being Martinotti-cells, characterised by dense dendritic
82 trees and long translaminar axons (Riedemann 2019). SST-neurons target the distal dendrites of
83 pyramidal cells and, interestingly, other inhibitory neurons like Vasoactive intestinal polypeptide
84 (VIP)-expressing neurons and Parvalbumin (PV)-expressing neurons (Pfeffer et al. 2013; Riedemann
85 2019; Xiao et al. 2020), making these cells able to influence both excitation and inhibition in the
86 network. Moreover SST-neurons seem to be involved in network plasticity, often through the
87 inhibition of PV-neurons (Cummings and Clem 2020; Sadahiro et al. 2020; Tang et al. 2014).
88
89 SST-neurons in the Nucleus Accumbens have a bi-directional control over both the cocaine-induced
90 hyperlocomotion and the cocaine-conditioned place preference (Ribeiro et al. 2018). Considering
91 the strong involvement of neural plasticity and SST-neurons in the regulation of the addictive
92 behaviour we decided to study the specific role of the BDNF/TrkB pathway in SST-neurons. With
93 the use of mice expressing a heterozygous knockout of the *TrkB* gene (SST-TrkB-hCKO mice) and
94 the conditioned place preference (CPP) paradigm (Itzhak and Martin 2002), we observed that
95 while the *wt* group successfully reduced its cocaine-conditioning after a week of extinction
96 training, the SST-TrkB-hCKO mice did not. However, both groups showed cocaine-induced
97 reinstatement when tested a month later. We then specifically activated TrkB in SST-neurons in the
98 Infralimbic cortex (ILCx) during the extinction training, by using, a sensitive type of optically
99 activatable TrkB (E281A)(Hong and Heo 2020) with a mouse line expressing the *Cre* recombinase
100 only in SST-neurons, and found that TrkB activation prevented relapse. This research provides
101 evidence for the role of TrkB-mediated neural plasticity and SST-neurons in the extinction of a
102 cocaine-conditioning and in the suppression of relapse. Our findings highlight the potential of
103 targeting the BDNF/TrkB pathway in SST-neurons as a promising therapeutic strategy to consolidate
104 extinction and reduce the risk of relapse in addiction treatments.
105

106 **2. Materials and methods**

107 ***Generation of mice***

108 Heterozygous TrkB knock out mice specifically in SST-neurons (SST-TrkB-hCKO) were generated by
109 mating mice from a mouse line expressing the *Cre* recombinase in SST neurons (SST^{Cre/Cre}; SST-IRES-
110 *Cre*, RRID:IMSR_JAX:013044, Jackson Laboratory) with mice from a heterozygous line carrying
111 floxed alleles of *Ntrk2*, the gene encoding for TrkB (TrkB^{flx/wt}) (Minichiello et al. 1999) and *wt*
112 littermate as controls. For the optogenetic experiment, we crossed SST^{Cre/Cre} with *wt* mice to
113 generate SST^{Cre/wt} mice. The mice were kept in IVC cages with food and water *ad libitum*, with a 12-
114 hours light/dark cycle, with light turning on at 6:00 am.
115

116 ***Conditioned Place Preference (CPP)***

117 The conditioned place preference (CPP) setup involved a Plexiglas box measuring 460x460x400mm
118 and included removable floor panels of very different materials (smooth metal plates with holes
119 (Type A) and rough plastic plates (Type B)). Each panel covered half of the box's floor, requiring two

120 panels to cover the entire surface. This allowed 4 possible combinations of floor configuration: AA;
121 BB; AB; BA. The box was integrated into a system utilizing infrared signals to track the mouse's
122 position in real time, and a camera positioned above the box recorded the tests. To record the
123 animals position we used the software TSE Multi Conditioning System.

124 The behavioural paradigm used for the CPP (**Fig.1**) test was:

125 **Day 1: Pre-test 1:**

126 Mice were injected with saline and placed in the box with Type A flooring on one half and Type B
127 on the other for 20 minutes.

128 **Day 2: Pre-test 2:**

129 Mice received another saline injection and were again exposed to Type A flooring on one side and
130 Type B on the other for 20 minutes.

131 During these phases, we checked the mice's initial preferences between the two floor types.

132 Generally, preferences observed in Pre-Test 1 were consistent with those in Pre-Test 2. If results
133 differed, we used the outcomes of Pre-Test 2. The results from these tests helped ensure that
134 cocaine treatment was always paired with the less preferred floor type, while control treatment
135 (saline injection) was associated with the preferred floor type.

136 **Days 5-9: Conditioning:**

137 In the morning the mice underwent control treatment and were placed on the corresponding floor
138 type. In the afternoon, they received cocaine treatment (20 mg/kg dissolved in saline, IP injection)
139 and were placed on the corresponding floor type. The sessions lasted 15 min each.

140 **Day 10: Conditioning Test:**

141 Mice were injected with saline and exposed to Type A flooring on one side and Type B on the other
142 for 10 minutes.

143 This test assessed the level of conditioning. Mice were considered "conditioned" if they spent
144 more than 50% of the time on the side associated with cocaine. Those that did not meet this
145 criterion were excluded from the experiment.

146 **Days 12-17: Extinction Phases:**

147 Mice received saline injections and were exposed to Type A flooring on one side and Type B on the
148 other for 10 minutes.

149 Repeated exposure to both floor types in the absence of cocaine typically reduced preference until
150 a roughly equal (50-50) preference was reached, indicating no preference.

151 **Day 18: Extinction Test:**

152 Mice received saline and were exposed to Type A flooring on one side and Type B on the other for
153 10 minutes.

154 We used this test to determine the success of the extinction training.

155 **Day 47: Remote Memory Test:**

156 Mice received a saline injection and were exposed to Type A flooring on one side and Type B on
157 the other for 10 minutes.

158 We used this test to measure the long-term effects of extinction.

159 **Day 48: Reinstatement Test:**

160 Mice were given a half dose of cocaine (10 mg/kg dissolved in saline, IP injection) and exposed to
161 Type A flooring on one side and Type B on the other for 10 minutes.

162 This test models "relapse" (Shaham et al. 2003) and relies on the persistence of the neural
163 association between the cocaine stimulus and the cocaine-associated floor type.

164

165 ***Open Field Test***

166 The Open Field box consisted of a 30 x 30 cm square arena provided by Med Associates, with
167 transparent walls and a white smooth floor. Infrared sensors installed in the arena tracked both
168 horizontal and vertical movements, recording the total distance travelled throughout the 10-
169 minute test period. The arena was illuminated to approximately 150 lx. The peripheral zone was
170 defined as a 6 cm wide strip along the edges of the walls.

171

172 ***Immunohistochemistry***

173 The brain slices were initially washed and permeabilized with a solution of PBS and 0.1% TritonX®
174 (PBST) for 10 minutes at room temperature. Next, the samples were incubated in a blocking buffer
175 composed of 3% Bovine Serum Albumin (BSA) in PBST for 1 hour at room temperature. Following
176 the blocking step, I applied specific primary antibody solution (Rabbit anti-cFos, sc-052, SantaCruz
177 (Dallas, Texas, USA), 1:300 in PBST) to the samples. The antibody was incubated with the samples
178 overnight at 4°C. The next day, I washed the samples three times, 10 minutes each, with PBST at
179 room temperature. Next, the samples were incubated with secondary antibody solution containing
180 anti-Rabbit IgG conjugated to Alexa647 fluorophore (Goat anti-rabbit IgG, Alexa647,
181 Jackson Laboratory (Bar Harbor, Maine, USA), 1:800), diluted in PBST, for 2 hours at room
182 temperature. After this step, the samples were washed three more times for 10 minutes each with
183 PBST at room temperature, followed by a final wash with 0.1M phosphate buffer (PB 0) for 5
184 minutes. Finally, I mounted the samples on glass slides using Dako® mounting media and left them
185 to dry overnight at room temperature, protected from light.

186

187 ***Brain lysates analysis***

188 The mice were euthanized with CO₂, followed by cervical dislocation. We extracted the brain and
189 isolated the mPFC while keeping everything on ice. The tissues were placed into 250 µL of lysis
190 buffer containing NP40, vanadate as a phosphatase inhibitor, and a cocktail of protease inhibitors.
191 We dissociated the tissue mechanically using a tissue disruptor. We measured the protein
192 concentration using the BioRad DC Protein Assay, and the samples were then diluted with fresh
193 lysis buffer to achieve uniform concentrations across all samples. Subsequently, the samples were
194 denatured using Laemmli buffer and placing them at 100 °C for 5 minutes. We run the samples
195 onto NuPage™ 15-well gels (4-12% Bis-Tris gel) at 180 V until the 15 kDa marker exited the gel. The
196 proteins were then transferred to a PVDF membrane using a blotting device at 100 V for 1.5 hours
197 at 4°C. The membranes were washed with Tris Buffer Solution containing 0.001% Tween® 20 (TBST)
198 for 5 minutes, then blocked with a blocking buffer (TBST + 3% BSA) for 1 hour at room
199 temperature. Following blocking, the membranes were incubated with primary antibody solutions
200 (p-CREB: #9198 Cell Signalling Technology, 1:1000; CREB: #4820 Cell Signalling Technology, 1:1000;
201 HA: #2367 Cell Signalling Technology, 1:500; all antibodies were diluted in TBST + 3% BSA) at 4°C for
202 24 to 48 hours. Next, the membranes were washed three times with TBST for 10 minutes each and
203 incubated with secondary antibody solutions (HRP-conjugated secondary antibodies: Bio-RAD
204 #1705045 or #1705047, diluted 1:10000 in TBST + 5% Non-Fat Dry Milk) for 2 hours at room
205 temperature. After additional three washes with TBST for 10 minutes each, the membranes were
206 treated with HRP substrate (Pierce™ ECL+, Thermo Scientific®) for 5 minutes at room temperature.

207 The membranes were developed using a Syngene G:BOX device. The data was analysed using
208 ImageJ.

209

210 ***Image acquisition and analysis***

211 The imaging of the slices was performed using a confocal microscope Zeiss LSM 780 or a widefield
212 microscope Leica Thunder Imager 3D Cell Culture. The cFos analysis was performed by counting
213 the positive nuclei and normalising the count on the area considered (ROI). The ROI was identified
214 using the Allen Brain Atlas. The imaging was performed with the support of the Biomedicum
215 Imaging Unit. We analyse the images using either Fiji ImageJ or Imaris 10.1.

216

217 ***optoTrkB infection in the infralimbic cortex***

218 We anesthetized the mice with Isoflurane and secured their heads in a stereotactic frame. We
219 administered a subcutaneous injection of Carprofen (5 mg/kg) for pain relief, shaved the fur over
220 the head of the mice, cleaned the area with Medetomidine, and made a single incision to expose
221 the skull. The skull was cleaned with ethanol and air-dried. We drilled holes in the skull at the
222 following coordinates: 1.78mm from Bregma, +/- 0.7mm from the midline and -2.3 from the Dura
223 Mater, so that with an injector carrying an inclination of 10° from the vertical axes, we could target
224 specifically the infralimbic cortex. With a glass capillary loaded with the viral solution attached to
225 an automatic injector (Stoelting Integrated Stereotactic Injector system) we injected the virus in
226 the brain. The injection flow rate was set at 100 nl/min, and the capillary remained in place for 8
227 minutes following the injection. After the 8 minutes had elapsed, we carefully removed the
228 capillary and closed the incision with histoglu (3M™ Vetbond™ Tissue Adhesive). The mice were
229 placed on a heating pad to recover before being returned to their home cages.

230

231 ***Transparent skull surgery and metal holder implant***

232 This procedure was slightly adapted starting from a previous methods developed and published by
233 our lab in 2017 (Steinzeig, Molotkov, and Castrén 2017). Two weeks after the viral infection, the
234 mice were anesthetized with Isoflurane and secured on a stereotactic frame. After shaving the fur
235 from their heads, we disinfected the exposed skin with 70% ethanol. The skin was then incised to
236 reveal the skull, which was cleaned with acetone and sterile saline. To improve adhesion in the
237 next step, I made a grid-like incision on the skull using a disinfected scalpel. I applied Loctite glue to
238 the skull and allowed it to dry for roughly 5 minutes. Next, the metal holder (Steel430 ring with
239 8mm of outer diameter and 4 mm of inner diameter and 1mm of thickness. Custom design from
240 Hubs.com) was attached with Loctite, ensuring the inner hole was positioned directly over the
241 mPFC of the mouse. After another 5-minute drying period, we applied dental cement (Tetric
242 EvoFlow) and solidified it using a UV lamp. Next, we prepared an acrylic mixture by combining
243 colourless acrylic powder (EUBECOS, Germany) with methyl methacrylate liquid (Dentsply,
244 Germany). I added a drop into the inner hole of the metal holder, then the mouse was placed on a
245 heating pad to recover before being returned to its home cage.

246

247 ***LED activation of optoTrkB***

248 The setup involved optic fibers descending from above into the test box. We utilized a BioLED light
249 source Control Module (Mightex) that was interfaced with the computer running the behavioral

250 testing software, allowing for automated activation of the LED during the behavioural test. This
251 module was connected to a single-color LED device (BLS Super High Power Fiber-Coupled LED Light
252 Source, 470 nm Blue, Mightex). The LED device was linked to an optical connector wire, which
253 connected to an optic fibre (custom ordered from ThorLabs) via a rotary joint (Rotary Joint
254 Multimode Fiber Patchcord, 0.37 NA, 200 μ m Core, Mightex). These fibres terminated in a magnet,
255 which clipped onto the metal holder positioned above the mouse's PFC. The mice received pulses
256 of 1s for the whole duration of the behavioural test (10 min) with an ITI of 5s.

257

258 ***CPP with optoTrkB***

259 We integrated the CPP paradigm with an optogenetic system. The mice equipped with a
260 ferromagnetic-steel (steel430, company, and city?) metal holder around a transparent skull
261 window for connecting to an optical fibre via a small, disk-shaped magnet that attached
262 magnetically to the metal holder. This setup positioned the optical fibre above their prefrontal
263 cortex (PFC). During the extinction phases, blue LED light was delivered through the optical fibre
264 right over the PFC (**Fig.1**).

265

266 ***Statistical analysis***

267 All the statistical tests were performed using GraphPad Prism. The data was tested using T-
268 Test/Mann-Whitney, Wilcoxon test or a two-way ANOVA, depending on the number of variables
269 considered and on the nature of the distribution of the data. Outliers were identified using the
270 ROUT method (Motulsky and Brown 2006) with a Q value of 1, and any detected outliers resulted
271 in the exclusion of that particular mouse from the specific analysis. A p-value of less than 0.05 was
272 considered statistically significant.

273

274 **3. Results**

275 **TrkB in SST is necessary for the extinction of cocaine-induced CPP**

276 For studying the role of neural plasticity in somatostatin expressing (SST) neurons in the
277 development and extinction of cocaine-seeking behaviour, we performed the CPP paradigm using
278 heterozygous conditional TrkB knockout mice (SST-TrkB hCKO) and wildtype littermate controls (wt)
279 (**Fig.1A**). First, we conditioned the mice pairing cocaine and a distinguishable floor (plastic or
280 metal). The mice showed a preference for the cocaine-associated floor and the proportion of
281 conditioned mice seemed to be lower in SST-TrkB hCKO (43%) compared to wt littermate controls
282 (70%), however, this effect did not reach statistical significance (χ^2 -test, wt vs SST-TrkB-hCKO: $p =$
283 0.0579) (**Fig. 2B, Suppl. Fig. 1A-B**). To test the involvement of TrkB in SST neurons in the extinction
284 of cocaine-seeking behaviour, the conditioned mice underwent an extinction training, with the aim
285 of reducing the acquired preference by repeatedly exposing the mice to both the cocaine-
286 associated and saline-associated floors without the drug. We observed that the wt control mice
287 showed an expected reduction in preference (Paired T-test, $p = 0.0028$) (**Fig. 2C**). In contrast, the
288 SST-TrkB hCKO mice continued to maintain their preference even after seven days of extinction
289 training (Paired T-test, $p = 0.6879$). A month later, both groups underwent a remote memory test
290 (RM) and a reinstatement test to assess relapse. Both groups demonstrated a preference for the
291 floor pattern previously linked to cocaine, with SST-TrkB-hCKO even showing an increase in CPP
292 (RM T-test, wt $p = 0.0505$; SST-TrkB-hCKO $p = 0.022$; Reinstatement T-test, wt $p = 0.445$; SST-TrkB-

293 hCKO $p = 0.263$) (**Fig. 2 D, E**), indicating that the extinction did not occur in the SST-TrkB hCKO mice,
294 and that in the *wt* mice, it was not lasting long enough to prevent relapse.
295 Since we observed a difference in the levels of extinction between the SST-TrkB-hCKO and the *wt*
296 mice, we thought of checking whether there was any difference in the activation of neural
297 networks associated with the promotion of extinction and inhibition of relapse, like the IL-Cx and
298 the NuAcc (Bahi, Boyer, and Dreyer 2008; Chauvet et al. 2009; Hastings et al. 2020; LaLumiere,
299 Niehoff, and Kalivas 2010; Nestler 2005; Peters, LaLumiere, and Kalivas 2008). One hour after the
300 relapse test, we euthanized the mice and measured the levels of cFos, an immediate early gene
301 that is expressed in response to recent neural activity (Hudson 2018) and found no significant
302 differences in recent activation between the SST-TrkB hCKO mice and their *wt* littermates (**Fig. 2 F**)
303 both in the mPFC (2-way ANOVA mPFC, Genotype $F(1, 33) = 0.229, p = 0.635$) and in the NuAcc (T-
304 test, $p = 0.688$). However, the 2-way ANOVA test in the mPFC highlighted a difference in the levels
305 of cFos between the two brain areas forming the mPFC, suggesting a higher level of neural
306 activation in the infralimbic cortex (IL-Cx) compared to the Prelimbic cortex (PL-Cx) (2-way ANOVA
307 mPFC, brain area $F(1, 33) = 6.650, p = 0.0146$). This led us to hypothesize that neural plasticity, in
308 SST neurons, in this very area could be manipulated to consolidate the extinction training network
309 and prevent relapse.


310

311 **TrkB activity in SST neurons is sufficient to inhibit the reinstatement of cocaine-induced CPP**


312 We hypothesized that enhanced neural plasticity in SST-neurons during extinction training might
313 strengthen the extinction and prevent the relapse rate of cocaine-seeking behaviour. To regulate
314 neural plasticity specifically in the SST neurons, we transduced a sensitive version of optoTrkB
315 (optoTrkB (E821A)) (Hong and Heo 2020; Lilja et al. 2022) (**Fig. 3A**) into the IL-Cx of SST-cre mice.
316 Immunohistochemistry for the HA-tagged optoTrkB confirmed the correct location of optoTrkB and
317 its colocalization with SST (**Fig. 3B, D**). LED exposure significantly increased pCREB levels in the IL-
318 Cx lysates of these mice compared to unstimulated control mice (Mann Whitney test, $p = 0.0043$)
319 (**Fig. 3C**), confirming the activation of the downstream pathway of BDNF/TrkB (Finkbeiner et al.
320 1997; Minichiello et al. 2002). We also observed a significant difference in the levels of pCREB
321 between the unstimulated infected mice and uninfected controls (**Supp. Fig. 2E**), which may be
322 produced by some spontaneous activation of TrkB upon overexpression (Koponen, Võikar, et al.
323 2004; Koponen, Lakso, and Castrén 2004; Schecterson and Bothwell 2010). We conducted a CPP
324 experiment with SST-optoTrkB mice, and during the extinction training we exposed blue light
325 ($\lambda=470$ nm, 1s exposure with 5s ITI, for 10 min) to activate optoTrkB in SST neurons (**Fig. 1A**). As
326 expected, SST-optoTrkB mice exposed to LED developed a clear conditioning place preference as
327 the *wt* mice did (Paired T-test, $p < 0.0001$) (**Fig. 2B**). The SST-optoTrkB showed a significantly
328 decreased preference after six days of extinction training (Paired T-test, $p = 0.0342$) (**Fig. 2C**). When
329 tested for remote memory, the mice seemed to be still benefiting from the effects of the extinction
330 training (Paired T-test, $p = 0.0095$), showing low levels of cocaine-place preference (**Fig. 2D**). Most
331 interestingly, the LED group showed no increase in freezing, in the reinstatement test for relapse
332 (Paired T-test, $p = 0.0038$) (**Fig. 2 A; E**), suggesting an enhanced effect of extinction training with
333 the optoTrkB activation. The unstimulated control mice also showed similar results as the
334 stimulated mice in the extinction, remote memory, and reinstatement tests (Extinction Paired T-
335 test, $p = 0.0109$; RM Wilcoxon, $p = 0.1289$; Reinstatement Paired T-test, $p = 0.0128$) (**Supp. Fig. 2B-
336 D**), which is consistent with the increase in pCREB baseline levels in the absence of LED stimulation

337 and suggests that the spontaneous TrkB activation due to overexpression of TrkB in SST neurons in
338 the IL-Cx might be sufficient to inhibit relapse. Notably, when comparing each mouse's preference
339 in the RM test to its own preference right after conditioning, only the LED group had a statistically
340 significant shift in preference (LED-group, Paired T-test, $p = 0.0095$; no-LED group, Wilcoxon, $p =$
341 0.1289) (Fig. 1D; Supp. Fig. 2C), suggesting a more solid effect in the optoTrkB activated group.
342

A Condition place preference test (CPP)




B Optical TrkB activation in SST neurons




343
344 **Fig. 1:** Schematic representation of the experimental design. **A.** Schematic representation of the
345 CPP paradigm. Every mouse was exposed to a control conditioning involving saline injection and
346 exposure to the “control floor pattern”, and then expose to the cocaine conditioning involving a
347 cocaine injection and exposure to the “cocaine floor pattern”. When exposed to both floor
348 patterns, a conditioned mouse would spend most the time on the cocaine floor pattern. **B.**
349 Experimental design of the optogenetic activation of TrkB during CPP extinction. One month before
350 the CPP, the mice were transduced with an AAV vector carrying optoTrkB. Three weeks later the

351 mice underwent a procedure to make the skull transparent and to implant a metal holder above
352 the IL-Cx. 9 days later the mice underwent the CPP paradigm. During each phase of the CPP, the
353 mice had an optic fibre clipped magnetically to their metal holder. The light was turned ON only
354 during the seven days of extinction training. Image created with Biorender.com
355



356
357 **Fig.2:** Results from CPP paradigm of wt (N=17, black), SST-TrkB-hCKO mice (N=10, orange) and mice
358 infected with optoTrkB and exposed to LED light (N=10, blue). In figures B-F each dot represents a
359 mouse. **A.** Time course of the whole experiment. **B.** Paired T-tests of the different groups between
360 their baseline behaviour and their preference after 5 days of conditioning. Paired T-tests: wt p <
361 0.0001; SST-TrkB-hCKO p < 0.0001; optoTrkB + LED p < 0.0001. **C.** Preference between the post-
362 conditioning test and after a week of extinction training. Paired T-tests: wt p = 0.0028; SST-TrkB-
363 hCKO p = 0.6879; optoTrkB + LED p = 0.0342. **D.** Preference between the post-conditioning test and

364 the remote memory test. Paired T-tests: *wt* p = 0.0505; SST-TrkB-hCKO p = 0.0221; optoTrkB + LED
365 p = 0.0095. **E**. Preference between post-conditioning test and reinstatement test. Paired T-test: *wt*
366 p = 0.445; SST-TrkB-hCKO p = 0.263; optoTrkB + LED p = 0.0038. **F**. Count of cFos-positive nuclei
367 normalised on the area of ROI. Two-way ANOVA of mPFC: Genotype F (1, 33) = 0.229, p = 0.635;
368 brain area F 1 (1, 33) = 6.650, p = 0.0146. Nucleus Accumbens T-test p = 0.688.
369



370
371 **Fig. 3: Assessment of optoTrkB E281A.** **A.** Schematic representation of the structure of optoTrkB.
372 The construct presents the intracellular domain of TrkB bound to a Photolyse Homology Region
373 (PHR) and a HA-tag. The localisation of optoTrkB to the membrane is ensured by a Lyn sequence on
374 its N-terminus. Upon exposure to blue light, the PHR domain promotes the homodimerization of
375 the optoTrkB monomers, triggering the secondary messengers signalling cascade, leading to the
376 phosphorylation of CREB **B.** Western blot with antibody anti-HA tag. Vertical dotted bands identify
377 a mouse. For each mouse the infected area (IL-Cx) and a control area (Visual cortex, VC) is shown.

378 The HA-positive band is present only in the infected brain area of each mouse. **C.** Western blot
379 bands for phosphor-CREB and CREB and quantification. Mann Whitney test, $p = 0.0043$. **D.**
380 Confocal images of infralimbic cortex of mice infected with optoTrkB E281A. the HA tag is shown in
381 blue, SST is shown in red. The size bar in the low magnification image is 100 μm (on the left), while
382 in the image with higher magnification (on the right) is 20 μm .

383

384 **4. Discussion**

385 In this study, we assessed the role of TrkB in SST neurons in the development and extinction of
386 conditioning to cocaine. Our first approach consisted of impairing the BDNF/TrkB pathway in SST
387 neurons of mice that underwent a CPP paradigm. The main observation was the complete lack of
388 effectiveness of the extinction training on the SST-TrkB-hCKO mice that acquired the CPP. This
389 suggests how TrkB in SST neurons is necessary for extinguishing such conditioning. However, the
390 *wt* clearly benefited from the extinction training, showed a slight increase in preference one month
391 after the extinction training and showed a full relapse when tested for reinstatement. This implies
392 that the benefits of the extinction trainings were not long-lasting and did not delete the memory
393 associated to the conditioning to cocaine. We observed no difference in the levels of cFos between
394 the two groups one hour after the reinstatement test, neither in the IL-Cx nor in the NuAcc.
395 However, when including in the analysis the comparison between cFos in the IL-Cx and in the Pr-Cx
396 (brain area that promote cocaine-seeking behaviour (McFarland, Lapish, and Kalivas 2003), we saw
397 a significantly higher amount of cFos nuclei/ROI in the IL-Cx. A higher activity in the brain area
398 associated with extinction one hour after a test where the mice showed full relapse, might reflect a
399 persistence of an “extinction” neural network that competes with the “cocaine-seeking” network.
400 These observations made us hypothesise that if we were to promote plasticity in this “extinction”
401 network, we would be able to prevent relapse.

402

403 To enhance neural plasticity in SST neurons within the IL-Cx, we used an optogenetic TrkB receptor.
404 After assessing the correct location and activation of optoTrkB, we used it to consolidate neural
405 networks created during the extinction training and prevent relapse. The observations that mice
406 with optoTrkB activation during extinction training did not relapse suggests that TrkB activation in
407 SST neurons during extinction training is sufficient to consolidate the extinction network and
408 prevent relapse. Enhancement of behavioural flexibility has been obtained via different mean by
409 researchers. For example it has been shown how long-term ketamine administration can promote
410 fear erasure (Ju et al. 2017), injection of TrkB agonist in the IL-Cx promotes the extinction of CPP
411 (Otis, Fitzgerald, and Mueller 2014), and the psychedelic psilocybin has been shown to promote
412 behavioural flexibility in rats (Torrado Pacheco et al. 2023). Our lab has showed how manipulating
413 TrkB specifically in inhibitory neurons can lead to increased neural plasticity and induce
414 behavioural and network shifts that would otherwise happen only temporarily or wouldn’t happen
415 at all. For example, in 2011 and in 2023 our group showed how the plasticity-inducing
416 antidepressant drug fluoxetine consolidates the effects of a conditioned-fear extinction training,
417 preventing fear renewal and recovery, and that this was dependent on TrkB in the amygdala and
418 on TrkB specifically on parvalbumin (PV)-expressing inhibitory neurons (Jetsonen et al. 2023;
419 Karpova et al. 2011). Also in 2021 we showed how activating optogenetically TrkB in PV neurons in
420 the visual cortex of adult mice, it is possible to induce a shift of ocular dominance that usually

421 happens only in young mice (Winkel et al. 2021). We called this induced juvenile-like plasticity
422 “iPlasticity” (Umemori et al. 2018). Moreover, other research has further confirmed how
423 manipulating TrkB and/or inhibitory neurons we can induce a heightened state of neural plasticity
424 (Harauzov et al. 2010; Lensjø et al. 2017; Sale et al. 2007)
425 In this work we might be seeing a similar phenomenon. *Wt* mice already benefited from a CPP
426 extinction training, without the need of boosting its BDNF/TrkB pathway, but this beneficial effect
427 was not permanent, and relapse kicked in when the “cocaine-seeking network” was primed with a
428 drug cue, suggesting the existence of two neural networks (cocaine-seeking network and
429 extinction network) that would compete with each other. By boosting TrkB in the neurons relevant
430 for the extinction of the CPP (the SST neurons), in the relevant brain area (the IL-Cx), during the
431 relevant behavioural training (the extinction training), we selectively consolidated the “extinction
432 network”, forcing the competition in favour of the extinction, thus inhibiting relapse.
433
434 Interestingly, even mice expressing optoTrkB E821A without LED stimulation showed reduced
435 relapse. Given that both groups demonstrated strong cocaine-conditioned place preference after
436 the conditioning, and that cocaine-induced reinstatement is a well-established and widely
437 observed phenomenon (Aguilar, Rodríguez-Arias, and Miñarro 2009), our finding suggests that the
438 expression of optoTrkB E821A alone may enhance neural plasticity. This hypothesis is supported by
439 the observation that unstimulated optoTrkB-expressing mice had higher levels of pCREB than
440 uninfected controls. Trk receptors are known to auto-dimerize when overexpressed (Schecterson
441 and Bothwell 2010), and TrkB overexpression has been linked to increased neural plasticity *in vivo*
442 (Koponen, Vöikar, et al. 2004; Koponen, Lakso, et al. 2004). Therefore, our data suggests that
443 heightened TrkB activity, through either optogenetic means or overexpression in SST neurons in
444 the IL-Cx, coupled with a CPP extinction training, can support the extinction neural network, and
445 prevent relapse.

446

447 **5. Conclusion**

448 In this study, we demonstrated that TrkB activity in SST neurons is essential for a successful
449 extinction of cocaine-seeking behaviour in mice. Moreover, we found that by enhancing the
450 BDNF/TrkB signalling pathway in SST neurons during extinction training promotes extinction and
451 prevent relapse. As relapse is a major problem in addiction, these findings highlight the
452 importance of neural plasticity, particularly in inhibitory neurons, in the treatment of addictive
453 behaviours. Future studies are needed to assess the clinical implications of these observations to
454 develop more effective interventions that focus on preventing relapse.

455

456 **6. Acknowledgments**

457 We would like to thank Sulo Kolehmainen for the research support and for genotyping the mice,
458 Vootele Voikar, Nelli Koivisto and Aurora Hämäläinen for the constant support with the behavioural
459 setups and the caretakers of the animal facility of the University of Helsinki. We thank Dr. Anni-
460 Maija Linden for providing us the SST-cre mice used to generate our mice lines, and Dr. Jongryul
461 Hong and Dr. Won Do Heo for providing the plasmid of the optoTrkB E281A. The behavioural
462 experiments were carried out with the support of the Mouse Behavioural Phenotyping Facility
463 supported by Biocenter Finland and HiLIFE. The presented research was supported by the

464 Academy of Finland grants #2327192307416 and 347358, the Sigrid Jusélius foundation, Jane &
465 Aatos Erkko Foundation, the HiLife Fellows program, Bilateral exchange program between the
466 Academy of Finland and JSPS (Japan Society for the Promotion of Science).
467

468 **Conflict of interest statement**

469 The authors declare no conflict of interest.
470

471 **Ethical statement**

472 The experiments were carried out in accordance with the European Communities Council Directive
473 86/6609/EEC and the guidelines of the Society for Neuroscience and were approved by the County
474 Administrative Board of Southern Finland (License number: ESAVI/40845/2022).
475

476 **Author contributions**

477 G.D., TA, EC and J.U. designed the experiment, G.D. carried out the experiments and the analysis.
478 G.D., J.U. and E.C. wrote the manuscript.
479

480

481 References

482 Aguilar, Maria A., Marta Rodríguez-Arias, and Jose Miñarro. 2009. "Neurobiological Mechanisms of the
483 Reinstatement of Drug-Conditioned Place Preference." *Brain Research Reviews* 59(2):253–77. doi:
484 10.1016/J.BRAINRESREV.2008.08.002.

485 Bahi, Amine, Frederic Boyer, and Jean Luc Dreyer. 2008. "Role of Accumbens BDNF and TrkB in Cocaine-
486 Induced Psychomotor Sensitization, Conditioned-Place Preference, and Reinstatement in Rats."
487 *Psychopharmacology* 199(2):169–82. doi: 10.1007/S00213-008-1164-1/FIGURES/8.

488 Bath, Kevin G., Michael R. Akins, and Francis S. Lee. 2012. "BDNF Control of Adult SVZ Neurogenesis."
489 *Developmental Psychobiology* 54(6):578–89. doi: 10.1002/dev.20546.

490 Begni, Veronica, Marco Andrea Riva, and Annamaria Cattaneo. 2017. "Cellular and Molecular Mechanisms
491 of the Brain-Derived Neurotrophic Factor in Physiological and Pathological Conditions." *Clinical Science*
492 (*London, England : 1979*) 131(2):123–38. doi: 10.1042/CS20160009.

493 Bramham, Clive R., and Elhoccine Messaoudi. 2005. "BDNF Function in Adult Synaptic Plasticity: The
494 Synaptic Consolidation Hypothesis." *Progress in Neurobiology* 76(2):99–125. doi:
495 10.1016/J.PNEUROBIO.2005.06.003.

496 Brandon, Thomas H., Jennifer Irvin Virdrine, and Erika B. Litvin. 2007. "Relapse and Relapse Prevention." doi:
497 10.1146/annurev.clinpsy.3.022806.091455.

498 Chauvet, Claudia, Virginie Lardeux, Steven R. Goldberg, Mohamed Jaber, and Marcello Solinas. 2009.
499 "Environmental Enrichment Reduces Cocaine Seeking and Reinstatement Induced by Cues and Stress but
500 Not by Cocaine." *Neuropsychopharmacology* 34(13):2767–78. doi: 10.1038/npp.2009.127.

501 Crooks, Kristy R., Daniel T. Kleven, Ramona M. Rodriguez, William C. Wetsel, and James O. McNamara. 2010.
502 "TrkB Signaling Is Required for Behavioral Sensitization and Conditioned Place Preference Induced by a
503 Single Injection of Cocaine." 58(7):1067–77. doi: 10.1016/j.neuropharm.2010.01.014.TrkB.

504 Cummings, Kirstie A., and Roger L. Clem. 2020. "Prefrontal Somatostatin Interneurons Encode Fear
505 Memory." *Nature Neuroscience*. doi: 10.1038/s41593-019-0552-7.

506 Finkbeiner, Steven, Sohail F. Tavazoie, Anna Maloratsky, Kori M. Jacobs, Kristen M. Harris, and Michael E.
507 Greenberg. 1997. "CREB: A Major Mediator of Neuronal Neurotrophin Responses." *Neuron* 19(5):1031–47.
508 doi: 10.1016/S0896-6273(00)80395-5.

509 Graham, Danielle L., Scott Edwards, Ryan K. Bachtell, Ralph J. DiLeone, Maribel Rios, and David W. Self.
510 2007. "Dynamic BDNF Activity in Nucleus Accumbens with Cocaine Use Increases Self-Administration and
511 Relapse." *Nature Neuroscience* 10(8):1029–37. doi: 10.1038/nn1929.

512 Grimm, Jeffrey W., Lin Lu, Teruo Hayashi, Bruce T. Hope, Tsung-Ping Su, and Yavin Shaham. 2003. "Time-
513 Dependent Increases in Brain-Derived Neurotrophic Factor Protein Levels within the Mesolimbic Dopamine
514 System after Withdrawal from Cocaine: Implications for Incubation of Cocaine Craving." *Journal of*
515 *Neuroscience* 23(3):742–47. doi: 10.1523/JNEUROSCI.23-03-00742.2003.

516 Hall, F. Scott, Jana Drgonova, Michelle Goeb, and George R. Uhl. 2003. "Reduced Behavioral Effects of
517 Cocaine in Heterozygous Brain-Derived Neurotrophic Factor (BDNF) Knockout Mice."
518 *Neuropsychopharmacology* 28(8):1485–90. doi: 10.1038/sj.npp.1300192.

519 Harauzov, Alexey, Maria Spolidoro, Graziella DiCristo, Roberto De Pasquale, Laura Cancedda, Tommaso
520 Pizzorusso, Alessandro Viegi, Nicoletta Berardi, and Lamberto Maffei. 2010. "Reducing Intracortical

521 Inhibition in the Adult Visual Cortex Promotes Ocular Dominance Plasticity." *Journal of Neuroscience*
522 30(1):361–71. doi: 10.1523/JNEUROSCI.2233-09.2010.

523 Hastings, Margaret H., Jamie M. Gauthier, Kyle Mabry, Audrey Tran, Heng Ye Man, and Kathleen M. Kantak.
524 2020. "Facilitative Effects of Environmental Enrichment for Cocaine Relapse Prevention Are Dependent on
525 Extinction Training Context and Involve Increased TrkB Signaling in Dorsal Hippocampus and Ventromedial
526 Prefrontal Cortex." *Behavioural Brain Research* 386. doi: 10.1016/J.BBR.2020.112596.

527 Hong, Jongryul, and Won Do Heo. 2020. "Optogenetic Modulation of TrkB Signaling in the Mouse Brain."
528 *Journal of Molecular Biology* 432(4):815–27. doi: 10.1016/j.jmb.2020.01.010.

529 Hudson, Andrew E. 2018. "Chapter Twelve - Genetic Reporters of Neuronal Activity: C-Fos and G-CaMP6."
530 Pp. 197–220 in *Methods in Enzymology*. Vol. 603, *Chemical and Biochemical Approaches for the Study of*
531 *Anesthetic Function Part B*, edited by R. G. Eckenhoff and I. J. Dmochowski. Academic Press.

532 Itzhak, Yossef, and Julio L. Martin. 2002. "Cocaine-Induced Conditioned Place Preference in Mice: Induction,
533 Extinction and Reinstatement by Related Psychostimulants." *Neuropsychopharmacology* 26(1):130–34. doi:
534 10.1016/S0893-133X(01)00303-7.

535 Jetsonen, Elias, Giuliano Didio, Frederike Winkel, Maria Llach Pou, Chloe Boj, Laura Kuczynski-Noyau,
536 Vootele Võikar, Ramon Guirado, Tomi Taira, Sari E. Lauri, Eero Castrén, and Juzoh Umemori. 2023.
537 "Activation of TrkB in Parvalbumin Interneurons Is Required for the Promotion of Reversal Learning in
538 Spatial and Fear Memory by Antidepressants." *Neuropsychopharmacology : Official Publication of the*
539 *American College of Neuropsychopharmacology*. doi: 10.1038/S41386-023-01562-Y.

540 Jones, Susan, and Antonello Bonci. 2005. "Synaptic Plasticity and Drug Addiction." *Current Opinion in*
541 *Pharmacology* 5(1):20–25. doi: 10.1016/j.coph.2004.08.011.

542 Ju, Ling-Sha, Jiao-Jiao Yang, Lei Lei, Jiang-Yan Xia, Dan Luo, Mu-Huo Ji, Anatoly E. Martynyuk, and Jian-Jun
543 Yang. 2017. "The Combination of Long-Term Ketamine and Extinction Training Contributes to Fear Erasure
544 by Bdnf Methylation." *Frontiers in Cellular Neuroscience* 11. doi: 10.3389/fncel.2017.00100.

545 Kang, Hyejin, and Erin M. Schuman. 1995. "Long-Lasting Neurotrophin-Induced Enhancement of Synaptic
546 Transmission in the Adult Hippocampus." *Science (New York, N.Y.)* 267(5204):1658–62. doi:
547 10.1126/SCIENCE.7886457.

548 Karpova, Nina N., Anouchka Pickenhagen, Jesse Lindholm, Ettore Tiraboschi, Natalia Kulesskaya, Arna
549 Ágústsdóttir, Hanna Antila, Dina Popova, Yumiko Akamine, Regina Sullivan, René Hen, Liam J. Drew, and Eero
550 Castrén. 2011. "Fear Erasure in Mice Requires Synergy between Antidepressant Drugs and Extinction
551 Training." *Science* 334(6063):1731–34. doi: 10.1126/science.1214592.

552 Klein, R., L. F. Parada, F. Coulier, and M. Barbacid. 1989. "trkB, a Novel Tyrosine Protein Kinase Receptor
553 Expressed during Mouse Neural Development." *The EMBO Journal* 8(12):3701–9. doi: 10.1002/j.1460-
554 2075.1989.tb08545.x.

555 Klein, Rüdiger, Venkata Nanduri, Shuqian Jing, Fabienne Lamballe, Peter Tapley, Sherri Bryant, Carlos
556 Cordon-Cardo, Kevin R. Jones, Louis F. Reichardt, and Mariano Barbacid. 1991. "The trkB Tyrosine Protein
557 Kinase Is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3." *Cell* 66(2):395–403.

558 Koob, George F., and Nora D. Volkow. 2010. "Neurocircuitry of Addiction." *Neuropsychopharmacology*
559 35(1):217–38. doi: 10.1038/npp.2009.110.

560 Koponen, Eija, Merja Lakso, and Eero Castrén. 2004. "Overexpression of the Full-Length Neurotrophin
561 Receptor trkB Regulates the Expression of Plasticity-Related Genes in Mouse Brain." *Brain Research.*
562 *Molecular Brain Research* 130(1–2):81–94. doi: 10.1016/j.molbrainres.2004.07.010.

563 Koponen, Eija, Vootele Võikar, Ruusu Riekki, Tommi Saarelainen, Tuomas Rauramaa, Heikki Rauvala, Tomi
564 Taira, and Eero Castrén. 2004. "Transgenic Mice Overexpressing the Full-Length Neurotrophin Receptor trkB
565 Exhibit Increased Activation of the trkB-PLC γ Pathway, Reduced Anxiety, and Facilitated Learning." *Molecular*
566 *and Cellular Neuroscience* 26(1):166–81. doi: 10.1016/j.mcn.2004.01.006.

567 Korte, M., P. Carroll, E. Wolf, G. Brem, H. Thoenen, and T. Bonhoeffer. 1995. "Hippocampal Long-Term
568 Potentiation Is Impaired in Mice Lacking Brain-Derived Neurotrophic Factor." *Proceedings of the National*
569 *Academy of Sciences* 92(19):8856–60. doi: 10.1073/pnas.92.19.8856.

570 LaLumiere, Ryan T., Kate E. Niehoff, and Peter W. Kalivas. 2010. "The Infralimbic Cortex Regulates the
571 Consolidation of Extinction after Cocaine Self-Administration." *Learning & Memory (Cold Spring Harbor, N.Y.)*
572 17(4):168–75. doi: 10.1101/lm.1576810.

573 Lee, Jaewon, Wenzhen Duan, and Mark P. Mattson. 2002. "Evidence That Brain-Derived Neurotrophic Factor
574 Is Required for Basal Neurogenesis and Mediates, in Part, the Enhancement of Neurogenesis by Dietary
575 Restriction in the Hippocampus of Adult Mice." *Journal of Neurochemistry* 82(6):1367–75. doi:
576 10.1046/j.1471-4159.2002.01085.x.

577 Lensjø, Kristian Kinden, Mikkel Elle Lepperød, Gunnar Dick, Torkel Hafting, and Marianne Fyhn. 2017.
578 "Removal of Perineuronal Nets Unlocks Juvenile Plasticity Through Network Mechanisms of Decreased
579 Inhibition and Increased Gamma Activity." *Journal of Neuroscience* 37(5):1269–83. doi:
580 10.1523/JNEUROSCI.2504-16.2016.

581 Li, Yun, Bryan W. Luikart, Shari Birnbaum, Jian Chen, Chang-Hyuk Kwon, Steven G. Kernie, Rhonda Bassel-
582 Duby, and Luis F. Parada. 2008. "TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to
583 Antidepressive Treatment." *Neuron* 59(3):399–412. doi: 10.1016/j.neuron.2008.06.023.

584 Lievens, Delfine, Freya Vander Laenen, and Johan Christiaens. 2014. "Public Spending for Illegal Drug and
585 Alcohol Treatment in Hospitals: An EU Cross-Country Comparison." *Substance Abuse Treatment, Prevention,*
586 *and Policy* 9(1):26. doi: 10.1186/1747-597X-9-26.

587 Lilja, Antonia, Giuliano Didio, Jongryul Hong, Won Do Heo, Eero Castrén, and Juzoh Umemori. 2022. "Optical
588 Activation of TrkB (E281A) in Excitatory and Inhibitory Neurons of the Mouse Visual Cortex." *International*
589 *Journal of Molecular Sciences* 23(18):10249. doi: 10.3390/IJMS231810249/S1.

590 McFarland, Krista, Christopher C. Lapish, and Peter W. Kalivas. 2003. "Prefrontal Glutamate Release into the
591 Core of the Nucleus Accumbens Mediates Cocaine-Induced Reinstatement of Drug-Seeking Behavior."
592 *Journal of Neuroscience* 23(8):3531–37. doi: 10.1523/JNEUROSCI.23-08-03531.2003.

593 Minichiello, L., M. Korte, D. Wolfer, R. Kühn, K. Unsicker, V. Cestari, C. Rossi-Arnaud, H. P. Lipp, T. Bonhoeffer,
594 and R. Klein. 1999. "Essential Role for TrkB Receptors in Hippocampus-Mediated Learning." *Neuron*
595 24(2):401–14. doi: 10.1016/s0896-6273(00)80853-3.

596 Minichiello, Liliana. 2009. "TrkB Signalling Pathways in LTP and Learning." *Nature Reviews Neuroscience*
597 10(12):850–60. doi: 10.1038/nrn2738.

598 Minichiello, Liliana, Anna Maria Calella, Diego L. Medina, Tobias Bonhoeffer, Rüdiger Klein, and Martin
599 Korte. 2002. "Mechanism of TrkB-Mediated Hippocampal Long-Term Potentiation." *Neuron* 36(1):121–37.
600 doi: 10.1016/S0896-6273(02)00942-X.

601 Motulsky, Harvey J., and Ronald E. Brown. 2006. "Detecting Outliers When Fitting Data with Nonlinear
602 Regression – a New Method Based on Robust Nonlinear Regression and the False Discovery Rate." *BMC
603 Bioinformatics* 7(1):123. doi: 10.1186/1471-2105-7-123.

604 Nestler, Eric J. 2005. "Is There a Common Molecular Pathway for Addiction?" *Nature Neuroscience*
605 8(11):1445–49. doi: 10.1038/nn1578.

606 Ostroumov, Alexey, and John A. Dani. 2018. "Inhibitory Plasticity of Mesocorticolimbic Circuits in Addiction
607 and Mental Illness." *Trends in Neurosciences* 41(12):898–910. doi: 10.1016/j.tins.2018.07.014.

608 Otis, James M., Michael K. Fitzgerald, and Devin Mueller. 2014. "Infralimbic BDNF/TrkB Enhancement of
609 GluN2B Currents Facilitates Extinction of a Cocaine-Conditioned Place Preference." *Journal of Neuroscience*
610 34(17):6057–64. doi: 10.1523/JNEUROSCI.4980-13.2014.

611 Patterson, Susan L., Ted Abel, Thomas A. S. Deuel, Kelsey C. Martin, Jack C. Rose, and Eric R. Kandel. 1996.
612 "Recombinant BDNF Rescues Deficits in Basal Synaptic Transmission and Hippocampal LTP in BDNF
613 Knockout Mice." *Neuron* 16(6):1137–45. doi: 10.1016/S0896-6273(00)80140-3.

614 Peters, Jamie, Ryan T. LaLumiere, and Peter W. Kalivas. 2008. "Infralimbic Prefrontal Cortex Is Responsible
615 for Inhibiting Cocaine Seeking in Extinguished Rats." *Journal of Neuroscience* 28(23):6046–53. doi:
616 10.1523/JNEUROSCI.1045-08.2008.

617 Pfeffer, Carsten K., Mingshan Xue, Miao He, Z. Josh Huang, and Massimo Scanziani. 2013. "Inhibition of
618 Inhibition in Visual Cortex: The Logic of Connections between Molecularly Distinct Interneurons." *Nature
619 Neuroscience* 16(8):1068–76. doi: 10.1038/NN.3446.

620 Poo, Mu-ming. 2001. "Neurotrophins as Synaptic Modulators." *Nature Reviews Neuroscience* 2(1):24–32.
621 doi: 10.1038/35049004.

622 Ribeiro, Efrain A., Marine Salery, Joseph R. Scarpa, Erin S. Calipari, Peter J. Hamilton, Stacy M. Ku, Hope
623 Kronman, Immanuel Purushothaman, Barbara Juarez, Mitra Heshmati, Marie Doyle, Casey Lardner,
624 Dominicka Burek, Ana Strat, Stephen Pirpinias, Ezekiell Mouzon, Ming Hu Han, Rachael L. Neve, Rosemary C.
625 Bagot, Andrew Kasarskis, Ja Wook Koo, and Eric J. Nestler. 2018. "Transcriptional and Physiological
626 Adaptations in Nucleus Accumbens Somatostatin Interneurons That Regulate Behavioral Responses to
627 Cocaine." *Nature Communications* 9(1). doi: 10.1038/s41467-018-05657-9.

628 Riedemann, Therese. 2019. "Diversity and Function of Somatostatin-Expressing Interneurons in the Cerebral
629 Cortex." *International Journal of Molecular Sciences* 20(12). doi: 10.3390/IJMS20122952.

630 Sadahiro, Masato, Michael P. Demars, Poromendro Burman, Priscilla Yevoo, Andreas Zimmer, and Hirofumi
631 Morishita. 2020. "Activation of Somatostatin Interneurons by Nicotinic Modulator Lypd6 Enhances Plasticity
632 and Functional Recovery in the Adult Mouse Visual Cortex." *Journal of Neuroscience* 40(27):5214–27. doi:
633 10.1523/JNEUROSCI.1373-19.2020.

634 Sale, Alessandro, José Fernando Maya Vetencourt, Paolo Medini, Maria Cristina Cenni, Laura Baroncelli,
635 Roberto De Pasquale, and Lamberto Maffei. 2007. "Environmental Enrichment in Adulthood Promotes
636 Amblyopia Recovery through a Reduction of Intracortical Inhibition." *Nature Neuroscience* 10(6):679–81.
637 doi: 10.1038/nn1899.

638 Schecterson, Leslayann C., and Mark Bothwell. 2010. "Neurotrophin Receptors: Old Friends with New
639 Partners." *Developmental Neurobiology* 70(5):332–38. doi: 10.1002/dneu.20767.

640 Shaham, Yavin, Uri Shalev, Lin Lu, Harriet De Wit, and Jane Stewart. 2003. "The Reinstatement Model of
641 Drug Relapse: History, Methodology and Major Findings." *Psychopharmacology* 168:3–20. doi:
642 10.1007/s00213-002-1224-x.

643 Steinzeig, Anna, Dmitry Molotkov, and Eero Castrén. 2017. "Chronic Imaging through 'Transparent Skull' in
644 Mice." *PLOS ONE* 12(8):e0181788. doi: 10.1371/JOURNAL.PONE.0181788.

645 Tang, Yunshuo, Michael P. Stryker, Arturo Alvarez-Buylla, and Juan Sebastian Espinosa. 2014. "Cortical
646 Plasticity Induced by Transplantation of Embryonic Somatostatin or Parvalbumin Interneurons." *Proceedings
647 of the National Academy of Sciences of the United States of America* 111(51):18339–44. doi:
648 10.1073/pnas.1421844112.

649 Torrado Pacheco, Alejandro, Randall J. Olson, Gabriela Garza, and Bita Moghaddam. 2023. "Acute Psilocybin
650 Enhances Cognitive Flexibility in Rats." *Neuropsychopharmacology* 48(7):1011–20. doi: 10.1038/s41386-
651 023-01545-z.

652 Tremblay, Robin, Soohyun Lee, and Bernardo Rudy. 2016. "GABAergic Interneurons in the Neocortex: From
653 Cellular Properties to Circuits." *Neuron* 91(2):260–92. doi: 10.1016/j.neuron.2016.06.033.

654 Umemori, Juzoh, Frederike Winkel, Giuliano Didio, Maria Llach Pou, and Eero Castrén. 2018. "iPlasticity:
655 Induced Juvenile-like Plasticity in the Adult Brain as a Mechanism of Antidepressants." *Psychiatry and
656 Clinical Neurosciences* 72(9):633–53. doi: 10.1111/pcn.12683.


657 Winkel, Frederike, Maria Ryazantseva, Mathias B. Voigt, Giuliano Didio, Antonia Lilja, Maria Llach Pou, Anna
658 Steinzeig, Juliana Harkki, Jonas Englund, Stanislav Khirug, Claudio Rivera, Satu Palva, Tomi Taira, Sari E. Lauri,
659 Juzoh Umemori, and Eero Castrén. 2021. "Pharmacological and Optical Activation of TrkB in Parvalbumin
660 Interneurons Regulate Intrinsic States to Orchestrate Cortical Plasticity." *Molecular Psychiatry* 26(12):7247–
661 56. doi: 10.1038/S41380-021-01211-0.

662 Xiao, Qian, Xinyi Zhou, Pengfei Wei, Li Xie, Yaning Han, Jie Wang, Aoling Cai, Fuqiang Xu, Jie Tu, and Liping
663 Wang. 2020. "A New GABAergic Somatostatin Projection from the BNST onto Accumbal Parvalbumin
664 Neurons Controls Anxiety." *Molecular Psychiatry* 1–23. doi: 10.1038/s41380-020-0816-3.

665


666

667



668
669
670
671
672
673
674
675
676
677

Suppl. Fig. 1: Data from conditioning test of the CPP between *wt* mice and the *SST-TrkB-hCKO* mice. **A.** Preference after five days of conditioning. T-test $p = 0.0896$. **B.** Number of mice that showed a preference for the cocaine-associated side above 0.5 (conditioned) and mice that showed a preference below or equal to 0.5 (unconditioned), between the two groups. χ^2 -test, *wt* vs *SST-TrkB-hCKO*: $p = 0.0579$.



678
679
680
681
682
683
684
685
686
687
688

Suppl. Fig. 2: Preference rate of optoTrkB mice without LED stimulation (N=9). **A.** Preference before and after five days of conditioning. Paired T-test $p < 0.0001$. **B.** Preference rate between post-conditioning test and after seven days of extinction training. Paired T-test, $p = 0.0109$. **C.** Preference rate between post-conditioning test and remote memory test. Wilcoxon, $p = 0.1289$. **D.** Preference between post-conditioning test and reinstatement. Paired T-test, $p = 0.0128$. **E.** Analysis of western blot bands of pCREB/CREB between optoTrkB w/o LED mice and uninfected controls. Mann-Whitney test, $p = 0.0065$. **F.** LED activation of optoTrkB has no effect on baseline locomotion. Mann Whitney test, $p = 0.6200$.